- US11771699utility2023Combined Treatment with a TLR7 Agonist and an HBV Capsid Assembly Inhibitor0 cites
- US11767363utility2023High Concentration Antibody-containing Liquid Formulation0 cites
- US11767342utility2023Method for in Vitro Glycoengineering of Antibodies0 cites
- US11753640utility2023Oligonucleotides for Modulating Tau Expression0 cites
- US11739095utility2023Substituted Benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepines as GABA a GAMMA1 Positive Allosteric Modulators0 cites
- US11738003utility2023Method for Administration0 cites
- US11739142utility2023Bispecific Anti-ccl2 Antibodies0 cites
- US11732036utility2023Antibody That Binds to VEGF-A and ANG2 and Methods of Use0 cites
- US11718680utility2023Combination Therapy of Anti-cd20/anti-cd3 Bispecific Antibodies and 4-1BB (CD137) Agonists0 cites
- US11718653utility2023Method for in Vitro Glycoengineering of an Erythropoiesis Stimulating Protein0 cites
- US11713327utility2023Heteroaryl Heterocyclyl Compounds for the Treatment of Autoimmune Disease0 cites
- US11708354utility20232-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide Compounds0 cites
- US11708344utility2023Flavone Derivatives for the Treatment and Prophylaxis of Hepatitis B Virus Disease0 cites
- US11697636utility2023Substituted Benzamides0 cites
- US11697079utility2023Separation Apparatus and Use Thereof0 cites
- US11697514utility2023Closing a Chamber of a Container for a Pharmaceutical Product0 cites
- US11685790utility2023Antibodies Binding to STEAP-10 cites
- US11680110utility2023Three-dimensional Structure-based Humanization Method0 cites
- US11679127utility2023Antigen Binding Receptors Specific for Mutated Fc Domains0 cites
- US11673945utility2023Bispecific Antigen Binding Proteins0 cites